21816-42-2

Basic information

• Product Name: 2,5-Dimethyl-4-nitropyridine 1-oxide
• Synonyms: 2,5-Dimethyl-4-nitropyridine 1-oxide;2,5-diMethyl-4-nitropyridine;Pyridine,2,5-dimethyl-4-nitro-, 1-oxide
• CAS NO: 21816-42-2
• Molecular Formula: C₇H₈N₂O₃
• Molecular Weight: 168.17
• Mol File: 21816-42-2.mol

Chemical Properties

• Boiling Point: 297.07°C (rough estimate)
• Flash Point: 191.9°C
• Appearance: /
• Density: 1.3722 (rough estimate)
• Vapor Pressure: 4.72E-06mmHg at 25°C
• Refractive Index: 1.5200 (estimate)
• CAS DataBase Reference: 2,5-Dimethyl-4-nitropyridine 1-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-Dimethyl-4-nitropyridine 1-oxide(21816-42-2)
• EPA Substance Registry System: 2,5-Dimethyl-4-nitropyridine 1-oxide(21816-42-2)

Safety Data

• Hazardous Substances Data: 21816-42-2(Hazardous Substances Data)

Usage

Uses

Used in Polymerization Industry:
2,5-Dimethyl-4-nitropyridine 1-oxide is used as a radical initiator for polymerization reactions, facilitating the formation of polymers through the initiation of radical chain reactions.
Used in Organic Synthesis:
In the field of organic synthesis, 2,5-Dimethyl-4-nitropyridine 1-oxide serves as a reagent, particularly for the oxidation of alcohols to carbonyl compounds, which is a crucial transformation in the synthesis of various organic molecules.
Used in Pharmaceutical Research:
2,5-Dimethyl-4-nitropyridine 1-oxide is utilized in pharmaceutical research for its potential biological activities, such as inhibiting the growth of various cancer cell lines, making it a compound of interest for the development of new therapeutic agents.
It is important to handle 2,5-Dimethyl-4-nitropyridine 1-oxide with care due to its potential harmful effects if ingested, inhaled, or if it comes into contact with the skin or eyes.

InChI:InChI=1/C7H8N2O3/c1-5-4-8(10)6(2)3-7(5)9(11)12/h3-4H,1-2H3

Upstream product

• 4986-05-4 2,5-dimethylpyridine N-oxide 
• 589-93-5 2,5-dimethylpyridine 
• 7664-93-9 sulfuric acid 

Downstream Products

• 1196157-14-8 4-bromo-5-methylpyridine-2-carbaldehyde 
• 820224-83-7 (4-bromo-5-methylpyridin-2-yl)methanol 
• 103577-41-9 2-[5-Methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethylsulfanyl]-1H-benzoimidazole 
• 94452-59-2 2-(chloromethyl)-4-methoxy-5-methylpyridine hydrochloride 
• 94452-65-0 2-hydroxymethyl-4-methoxy-5-methylpyridine 
• 155919-05-4 1,4-dihydro-5-methyl-3-nitro-4-oxo-2-pyridinecarboxylic acid 
• 155919-10-1 2,5-dimethyl-4-methoxypyridine 
• 193690-65-2 1,4,7-Trimethyl-1H-imidazo[4,5-c]pyridin-2-ylamine 
• 193690-64-1 3-amino-2,5-dimethyl-4-methylaminopyridine 
• 193690-61-8 2,5-dimethyl-4-methylaminopyridine 
• 22279-89-6 4-amino-2,5-dimethylpyridine 

Relevant articles and documents

6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B

A structure-activity relationship investigation of various 6-(azaindol-2-yl)pyridine-3-sulfonamides using the HCV replicon cell culture assay led to the identification of a potent series of 7-azaindoles that target the hepatitis C virus NS4B. Compound 2ac, identified via further optimization of the series, has excellent potency against the HCV 1b replicon with an EC50 of 2 nM and a selectivity index of >5000 with respect to cellular GAPDH RNA. Compound 2ac also has excellent oral plasma exposure levels in rats, dogs and monkeys and has a favorable liver to plasma distribution profile in rats.

Preparation method of 4 - bromo -2 - (difluoromethyl) -5 - methylpyridine

The invention belongs to the technical field of medical intermediates, and particularly relates to a preparation method of 4 - bromo -2 - (difluoromethyl) -5 - methylpyridine. The compound A is used as a raw material and is sequentially subjected to oxidation reaction, nitration reaction, substitution reaction, reduction reaction, hydrolysis reaction, oxidation reaction and fluoro reaction to prepare 4 - bromo -2 - (difluoromethyl) -5 - methylpyridine, and the prepared 4 -bromo -2 - (difluoromethyl) -5 -5 - 4 -methylpyridine is high in yield and high in purity -2 .

Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase

Non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-RT) are reported that incorporate a 7-indolizinylamino or 2-naphthylamino substituent on a pyrimidine or 1,3,5-triazine core. The most potent compounds show below 10 nanomolar activity towards wild-type HIV-1 and variants bearing Tyr181Cys and Lys103Asn/Tyr181Cys resistance mutations. The compounds also feature good aqueous solubility. Crystal structures for two complexes enhance the analysis of the structure-activity data.

HETEROARYL SUBSTITUTED INDOLE COMPOUNDS USEFUL AS MMP-13 INHIBITORS

Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I.

Syntheses of five potential heterocyclic amine food mutagens

The syntheses of the potential heterocyclic amine food mutagens, 3,5,7- trimethyl-2-aminoimidazo[4,5-b]pyridine, 1,4,7-trimethyl-2-aminoimidazo[4,5- c]pyridine, 1,6,7-trimethyl-2-aminoimidazo[4,5-c]-pyridine, 3,4,6-trimethyl- 2-aminoimidazo[4,5-c]pyridine, and 1,4,6-trimethyl-7-aminoimidazo[4,5-c]- pyridine are described.

Toward the design of an RNA:DNA hybrid binding agent

One characteristic function of the retroviruses, which is generally not found in normal eukaryotic cells, is production of a long RNA:DNA hybrid in the viral replication phase. If agents are designed which bind only to the RNA:DNA hybrid, but neither to DNA nor to RNA, such agents will be able to inhibit specifically the RNase H activity of retroviral reverse transcriptase, and therefore will suppress viral replication. Actinomycin D binds to double-stranded DNA, but not to RNA, because steric hindrance between the 2-amino group of the phenoxazinone ring and the 2'-hydroxyl group of RNA prevents intercalation of the antibiotic. However, if the C8-H in the phenoxazinone ring is replaced by an aromatic nitrogen N8, a strong hydrogen bond acceptor, this analog (N8-actinomycin D) might be able to bind intercalatively to an RNA:DNA hybrid by forming an additional hydrogen bond between N8 and the 2'-hydroxyl group of guanosine ribose. This hypothesis has been tested by a molecular mechanics calculation using a model structure of the complex between N8-actinomycin D and a small RNA:DNA hybrid, r(GC):d(GC). The results of the molecular mechanics calculation suggest that N8-actinomycin D can intercalatively bind to the RNA:DNA hybrid by making an additional intracomplex hydrogen bond. This hydrogen bonding capability of N8 has been confirmed in the crystal structure of the chromophore of N8-actinomycin D. Thus, N8-actinomycin D has been synthesized by coupling the pyridine and benzene fragments obtained independently. A binding study indicates that both actinomycin D and N8-actinomycin D bind intercalatively not only to DNA:DNA double strands but also to RNA:DNA hybrids. Although the overall binding capacity of N8-actinomycin D is reduced substantially in comparison with that of actinomycin D itself, N8-actinomycin D tends to bind relatively more favorably than actinomycin D to the RNA:DNA hybrids. Thus, this initial attempt at designing an RNA:DNA hybrid binding agent appears to be successful. However, it is necessary to modify the agent further to increase its RNA:DNA hybrid binding character and to decrease the DNA:DNA binding character, in order to make a useful RNA:DNA hybrid binding agent.

(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate

[(Pyridylmethyl)sulfinyl]benzimidazoles 1 (PSBs) are a class of highly potent antisecretory (H+,K+)-ATPase inhibitors which need to be activated by acid to form their active principle, the cyclic sulfenamide 4. Selective inhibitors of the (H+,K+)-ATPase in vivo give rise to the nonselective thiophile 4 solely at low pH, thus avoiding interaction with other thiol groups in the body. The propensity to undergo the acid-catalyzed transformation is dependent on the nucleophilic/electrophilic properties of the functional groups involved in the formation of 2 since this step is both rate-determining and pH-dependent. The aim of this study was to identify compounds with high (H+,K+)-ATPase inhibitory activity in stimulated gastric glands possessing acidic pH, but low reactivity (high chemical stability) at neutral pH as reflected by in vitro (Na+,K+)-ATPase inhibitory activity. The critical influence of substituents flanking the pyridine 4-methoxy substituent present in all derivatives was carefully studied. The introduction of a 3-methoxy group gave inhibitors possessing a combination of high potency, similar to omeprazole and lansoprazole, but increased stability. As a result of these studies, compound 1a (INN pantoprazole) was selected as a candidate drug and is currently undergoing phase III clinical studies.

Tricyclic imidazole derivatives

Tricyclic imidazole derivatives of formula I STR1 wherein one of R1 and R3 is lower alkyl and the other is hydrogen or lower alkyl, R2 is lower alkyl, n is the number 0 or 1, A is STR2 R4, R5, R6 and R7 each is lower alkyl and R8 is hydrogen or lower alkyl, and their acid addition salts are described. These compounds are useful as agents for control or prevention of ulcers and of increased gastric acid secretion.